aTYR PHARMA INC Income (Loss) from Continuing Operations before Income Taxes, Domestic
aTYR PHARMA INC (ATYR) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$73.89 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-05
- aTYR PHARMA INC income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$73.89M.
- aTYR PHARMA INC income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$64.09M.
- aTYR PHARMA INC income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$49.97M.
- aTYR PHARMA INC income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$45.09M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$73.89M 10-K · filed 2026-03-05 |
| 2024-12-31 | -$64.09M 10-K · filed 2026-03-05 |
| 2023-12-31 | -$49.97M 10-K · filed 2026-03-05 |
| 2022-12-31 | -$45.09M 10-K · filed 2025-03-13 |
| 2021-12-31 | -$33.32M 10-K · filed 2024-03-14 |
| 2020-12-31 | -$15.95M 10-K · filed 2023-03-14 |
| 2019-12-31 | -$23.32M 10-K · filed 2022-03-15 |
| 2018-12-31 | -$34.02M 10-K · filed 2021-03-24 |
| 2017-12-31 | -$47.71M 10-K · filed 2020-03-26 |
| 2016-12-31 | -$57.10M 10-K · filed 2019-03-26 |
| 2015-12-31 | -$47.49M 10-K · filed 2018-03-20 |
| 2014-12-31 | -$34.88M 10-K · filed 2017-03-16 |
| 2013-12-31 | -$11.09M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |